Project: Design of an anti-CD160 mAb targeting CLL, HCL and immune cells for leukemia immunotherapy
| Acronym | LeukeMab (Reference Number: 10865) |
| Duration | 01/03/2017 |
| Project Topic | The goal of the project is to develop a new monoclonal antibody (mAb) to treat B-Cell Chronic Lymphocytic Leukemia (CLL). The project partners will develop, produce, and validate a therapeutic mAb to simultaneously kill leukemia tumour cells and activate the antitumor immune response. This would be a major improvement in terms of efficacy and toxicity compared to current treatments. At the end of the project, the product will be ready to start regulatory and clinical development. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 6 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | ElsaLys Biotech | Coordinator | France |
| 2 | Deutsches Krebsforschungszentrum | Partner | Germany |